Company / Capital Expenditures
Veracyte, Inc. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$9.7M
FY2025
5-year range
$5.4M / $11.3M
FY2021-FY2025
Trend
-14.3%
vs FY2024
Sector context
#107 of 145
Health Care
What the data says
At $10M, Veracyte, Inc.'s capital expenditures ranks #107 of 145 in the Health Care sector. Declined from $10M to $10M over the past 2 years.
Based on SEC 10-K filings.
$10M in FY2025 with a 5-year CAGR of +27.8%.
Declined from $10M to $10M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +4.2%
- 5-Year CAGR
- +27.8%
- 10-Year CAGR
- -
Sector benchmark
#107 of 145 in Health CareTop 74% of 145This company $9.7M Sector average $268.6M
▼
-96.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +27.8%, indicating consistent growth.
- In FY2025, capital expenditures decreased 14.3% year-over-year.
- Ranks #107 out of 145 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 6.19 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $9.7M | -14.3% |
| FY2024 | $11.3M | +13.3% |
| FY2023 | $10.0M | +16.5% |
| FY2022 | $8.5M | +59.0% |
| FY2021 | $5.4M | +89.5% |
| FY2020 | $2.8M | +2.9% |
| FY2019 | $2.8M | +47.1% |
| FY2018 | $1.9M | +6.8% |
| FY2017 | $1.8M | -58.3% |
| FY2016 | $4.2M | -31.7% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026